Azathioprine and Risk of Skin Cancer in Organ Transplant Recipients: Systematic Review and Meta-Analysis

American Journal of Transplantation

Volumn 16, Issue 12, 2016, Pages 3490-3503

  Jiyad, Z ^a,b   Olsen, C M ^a,c   Burke, M T ^c   Isbel, N M ^c   Green, A C ^a,d  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^c UNIVERSITY OF QUEENSLAND   (Australia)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

antiproliferative agent: azathioprine (AZA); cancer malignancy neoplasia: risk factors; cancer malignancy neoplasia: skin; clinical research practice; dermatology; immunosuppressant; nonmelanoma

Indexed keywords

AZATHIOPRINE; REACTIVE OXYGEN METABOLITE; IMMUNOSUPPRESSIVE AGENT;

ARTICLE; BASAL CELL CARCINOMA; CANCER RISK; DRUG CARCINOGENICITY; DRUG EXPOSURE; GRAFT RECIPIENT; HUMAN; KERATINOCYTE; META ANALYSIS; ORGAN TRANSPLANTATION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SKIN CANCER; SKIN CARCINOMA; SYSTEMATIC REVIEW; CHEMICALLY INDUCED; GRAFT REJECTION; POSTOPERATIVE COMPLICATION; PROGNOSIS; RISK FACTOR; SKIN TUMOR; SQUAMOUS CELL CARCINOMA;

AZATHIOPRINE; CARCINOMA, BASAL CELL; CARCINOMA, SQUAMOUS CELL; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ORGAN TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; RISK FACTORS; SKIN NEOPLASMS;

EID: 84978152341     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.13863     Document Type: Article

References (89)

1. Ramsay HM, Fryer AA, Hawley CM, Smith AG, Harden PN. Non-melanoma skin cancer risk in the Queensland renal transplant population. Br J Dermatol 2002; 147: 950–956.
2. Wimmer CD, Rentsch M, Crispin A, et al. The janus face of immunosuppression—de novo malignancy after renal transplantation: The experience of the Transplantation Center Munich. Kidney Int 2007; 71: 1271–1278.
3. Jensen P, Hansen S, Moller B, et al. Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens. J Am Acad Dermatol 1999; 40(2 Pt 1): 177–186.
4. Hartevelt MM, Bavinck JN, Kootte AM, Vermeer BJ, Vandenbroucke JP. Incidence of skin cancer after renal transplantation in The Netherlands. Transplantation 1990; 49: 506–509.
5. Robbins HA, Clarke CA, Arron ST, et al. Melanoma risk and survival among organ transplant recipients. J Invest Dermatol 2015; 135: 2657–2665.
6. Clarke CA, Robbins HA, Tatalovich Z, et al. Risk of merkel cell carcinoma after solid organ transplantation. J Natl Cancer Inst 2015; 107: dju382.
7. Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. N Engl J Med 2003; 348: 1681–1691.
8. Aguiar B, Santos Amorim T, Romaozinho C, et al. Malignancy in kidney transplantation: A 25-year single-center experience in Portugal. Transpl Proc 2015; 47: 976–980.
9. Winkelhorst JT, Brokelman WJ, Tiggeler RG, Wobbes T. Incidence and clinical course of de-novo malignancies in renal allograft recipients. Eur J Surg Oncol 2001; 27: 409–413.
10. Tanner JE, Menezes J. Interleukin-6 and Epstein-Barr virus induction by cyclosporine A: Potential role in lymphoproliferative disease. Blood 1994; 84: 3956–3964.
11. Servilla KS, Burnham DK, Daynes RA. Ability of cyclosporine to promote the growth of transplanted ultraviolet radiation-induced tumors in mice. Transplantation 1987; 44: 291–295.
12. Herman M, Weinstein T, Korzets A, et al. Effect of cyclosporin A on DNA repair and cancer incidence in kidney transplant recipients. J Lab Clin Med 2001; 137: 14–20.
13. Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: A meta-analysis. Lancet 2007; 370: 59–67.
14. Perrett CM, Walker SL, O'Donovan P, et al. Azathioprine treatment photosensitizes human skin to ultraviolet A radiation. Br J Dermatol 2008; 159: 198–204.
15. Kelly GE, Meikle W, Sheil AG. Effects of immunosuppressive therapy on the induction of skin tumors by ultraviolet irradiation in hairless mice. Transplantation 1987; 44: 429–434.
16. O'Donovan P, Perrett CM, Zhang X, et al. Azathioprine and UVA light generate mutagenic oxidative DNA damage. Science 2005; 309: 1871–1874.
17. Sanders ML, Karnes JH, Denny JC, Roden DM, Ikizler TA, Birdwell KA. Clinical and genetic factors associated with cutaneous squamous cell carcinoma in kidney and heart transplant recipients. Transplant Direct 2015; 1: 1–7.
18. ANZDATA. Chapter 8: Transplantation. Australia and New Zealand dialysis and transplant registry. Adelaide, Australia; 2015.
19. Agency EM. EMA recommends additional measures to prevent use of mycophenolate in pregnancy. In. EMA/680077/2015 ed., 2015.
20. Molina BD, Leiro MG, Pulpon LA, et al. Incidence and risk factors for nonmelanoma skin cancer after heart transplantation. Transpl Proc 2010; 42: 3001–3005.
21. Bouwes Bavinck JN, Hardie DR, Green A, et al. The risk of skin cancer in renal transplant recipients in Queensland, Australia. A follow-up study. Transplantation 1996; 61: 715–721.
22. Ariyaratnam J, Subramanian V. Association between thiopurine use and nonmelanoma skin cancers in patients with inflammatory bowel disease: A meta-analysis. Am J Gastroenterol 2014; 109: 163–169.
23. Campbell SB, Walker R, Tai SS, Jiang Q, Russ GR. Randomized controlled trial of sirolimus for renal transplant recipients at high risk for nonmelanoma skin cancer. Am J Transplant 2012; 12: 1146–1156.
24. Euvrard S, Morelon E, Rostaing L, et al. Sirolimus and secondary skin-cancer prevention in kidney transplantation. N Engl J Med 2012; 367: 329–339.
25. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. J Clin Epidemiol 2009; 62: 1006–1012.
26. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: A proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000; 283: 2008–2012.
27. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: Guidelines for reporting observational studies. Lancet 2007; 370: 1453–1457.
28. Wong WC, Cheung CS, Hart GJ. Development of a quality assessment tool for systematic reviews of observational studies (QATSO) of HIV prevalence in men having sex with men and associated risk behaviours. Emerg Themes Epidemiol 2008; 5: 23.
29. Wells G, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2000.
30. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177–188.
31. Cochran WG. The combination of estimates from different experiments. Biometrics 1954; 10: 101–129.
32. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557–560.
33. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557–560.
34. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994; 50: 1088–1101.
35. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629–634.
36. Brewer JD, Colegio OR, Phillips PK, et al. Incidence of and risk factors for skin cancer after heart transplant. Arch Dermatol 2009; 145: 1391–1396.
37. Fuente MJ, Sabat M, Roca J, Lauzurica R, Fernandez-Figueras MT, Ferrandiz C. A prospective study of the incidence of skin cancer and its risk factors in a Spanish Mediterranean population of kidney transplant recipients. Br J Dermatol 2003; 149: 1221–1226.
38. Navarro MD, Lopez-Andreu M, Rodriguez-Benot A, Aguera ML, Del Castillo D, Aljama P. Cancer incidence and survival in kidney transplant patients. Transpl Proc 2008; 40: 2936–2940.
39. Mackenzie KA, Wells JE, Lynn KL, et al. First and subsequent nonmelanoma skin cancers: Incidence and predictors in a population of New Zealand renal transplant recipients. Nephrol Dial Transplant 2010; 25: 300–306.
40. Wisgerhof HC, Edelbroek JR, de Fijter JW, et al. Subsequent squamous- and basal-cell carcinomas in kidney-transplant recipients after the first skin cancer: Cumulative incidence and risk factors. Transplantation 2010; 89: 1231–1238.
41. Keller B, Braathen LR, Marti HP, Hunger RE. Skin cancers in renal transplant recipients: A description of the renal transplant cohort in Bern. Swiss Med Wkly 2010; 140: w13036.
42. van Leeuwen MT, Grulich AE, McDonald SP, et al. Immunosuppression and other risk factors for lip cancer after kidney transplantation. Cancer Epidemiol Biomark Prev 2009; 18: 561–569.
43. Gallagher MP, Kelly PJ, Jardine M, et al. Long-term cancer risk of immunosuppressive regimens after kidney transplantation. J Am Soc Nephrol 2010; 21: 852–858.
44. Geusau A, Dunkler D, Messeritsch E, et al. Non-melanoma skin cancer and its risk factors in an Austrian population of heart transplant recipients receiving induction therapy. Int J Dermatol 2008; 47: 918–925.
45. Mackintosh LJ, Geddes CC, Herd RM. Skin tumours in the West of Scotland renal transplant population. Br J Dermatol 2013; 168: 1047–1053.
46. Belloni-Fortina A, Piaserico S, Bordignon M, et al. Skin cancer and other cutaneous disorders in liver transplant recipients. Acta Derm Venereol 2012; 92: 411–415.
47. Ramsay HM, Fryer AA, Hawley CM, Smith AG, Nicol DL, Harden PN. Factors associated with nonmelanoma skin cancer following renal transplantation in Queensland, Australia. J Am Acad Dermatol 2003; 49: 397–406.
48. Ingvar A, Smedby KE, Lindelof B, et al. Immunosuppressive treatment after solid organ transplantation and risk of post-transplant cutaneous squamous cell carcinoma. Nephrol Dial Transplant 2010; 25: 2764–2771.
49. Einollahi B, Nemati E, Lessan-Pezeshki M, et al. Skin cancer after renal transplantation: Results of a multicenter study in Iran. Ann Transplant 2010; 15: 44–50.
50. Euvrard S, Kanitakis J, Decullier E, et al. Subsequent skin cancers in kidney and heart transplant recipients after the first squamous cell carcinoma. Transplantation 2006; 81: 1093–1100.
51. Hayashida MZ, Fernandes VM, de Melo Fernandes DR, Ogawa MM, Tomimori J. Epidemiology and clinical evolution of non-melanoma skin cancer in renal transplant recipients: A single-center experience in Sao Paulo, Brazil. Int J Dermatol 2015; 54: e383–e388.
52. Savoia P, Stroppiana E, Cavaliere G, et al. Skin cancers and other cutaneous diseases in renal transplant recipients: A single Italian center observational study. Eur J Dermatol 2011; 21: 242–247.
53. Serdar ZA, Eren PA, Canbakan M, et al. Dermatologic findings in renal transplant recipients: Possible effects of immunosuppression regimen and p53 mutations. Transpl Proc 2010; 42: 2538–2541.
54. Rashtak S, Dierkhising RA, Kremers WK, Peters SG, Cassivi SD, Otley CC. Incidence and risk factors for skin cancer following lung transplantation. J Am Acad Dermatol 2015; 72: 92–98.
55. Terhorst D, Drecoll U, Stockfleth E, Ulrich C. Organ transplant recipients and skin cancer: Assessment of risk factors with focus on sun exposure. Br J Dermatol 2009; 161(Suppl 3): 85–89.
56. Webb MC, Compton F, Andrews PA, Koffman CG. Skin tumours posttransplantation: A retrospective analysis of 28 years’ experience at a single centre. Transpl Proc 1997; 29: 828–830.
57. Gogia R, Binstock M, Hirose R, Boscardin WJ, Chren MM, Arron ST. Fitzpatrick skin phototype is an independent predictor of squamous cell carcinoma risk after solid organ transplantation. J Am Acad Dermatol 2013; 68: 585–591.
58. Caforio AL, Fortina AB, Piaserico S, et al. Skin cancer in heart transplant recipients: Risk factor analysis and relevance of immunosuppressive therapy. Circulation 2000; 102(19 Suppl 3): Iii222–Iii227.
59. Glover MT, Deeks JJ, Raftery MJ, Cunningham J, Leigh IM. Immunosuppression and risk of non-melanoma skin cancer in renal transplant recipients. Lancet 1997; 349: 398.
60. Hiesse C, Rieu P, Kriaa F, et al. Malignancy after renal transplantation: Analysis of incidence and risk factors in 1700 patients followed during a 25-year period. Transpl Proc 1997; 29: 831–833.
61. Fortina AB, Piaserico S, Caforio AL, et al. Immunosuppressive level and other risk factors for basal cell carcinoma and squamous cell carcinoma in heart transplant recipients. Arch Dermatol 2004; 140: 1079–1085.
62. Dantal J, Hourmant M, Cantarovich D, et al. Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: Randomised comparison of two cyclosporin regimens. Lancet 1998; 351: 623–628.
63. Lomas A, Leonardi-Bee J, Bath-Hextall F. A systematic review of worldwide incidence of nonmelanoma skin cancer. Br J Dermatol 2012; 166: 1069–1080.
64. Otley CC. Organization of a specialty clinic to optimize the care of organ transplant recipients at risk for skin cancer. Dermatol Surg 2000; 26: 709–712.
65. Stasko T, Brown MD, Carucci JA, et al. Guidelines for the management of squamous cell carcinoma in organ transplant recipients. Dermatol Surg 2004; 30(4 Pt 2): 642–650.
66. Ojo AO, Hanson JA, Wolfe RA, Leichtman AB, Agodoa LY, Port FK. Long-term survival in renal transplant recipients with graft function. Kidney Int 2000; 57: 307–313.
67. Jain A, Reyes J, Kashyap R, et al. Long-term survival after liver transplantation in 4000 consecutive patients at a single center. Ann Surg 2000; 232: 490.
68. Su F, Yu L, Berry K, et al. Aging of liver transplant registrants and recipients: Trends and impact on waitlist outcomes, post-transplantation outcomes, and transplant-related survival benefit. Gastroenterology 2015; 150: 441–453. e446
69. Barrett WL, First MR, Aron BS, Penn I. Clinical course of malignancies in renal transplant recipients. Cancer 1993; 72: 2186–2189.
70. Bichari W, Bartiromo M, Mohey H, et al. Significant risk factors for occurrence of cancer after renal transplantation: A single center cohort study of 1265 cases. Transpl Proc 2009; 41: 672–673.
71. Hung RKY, Cronin A, Rebollo MI, Frame S, Wain EM. Skin cancer and immunosuppression in long-term renal transplant recipients: A retrospective and case-controlled analysis. Br J Dermatol 2014; 171: 108.
72. Imao T, Ichimaru N, Takahara S, et al. Risk factors for malignancy in Japanese renal transplant recipients. Cancer 2007; 109: 2109–2115.
73. Jensen P, Hansen S, Moller B, Leivestad T, Pfeffer P, Fauchald P. Are renal transplant recipients on CsA-based immunosuppressive regimens more likely to develop skin cancer than those on azathioprine and prednisolone? Transpl Proc 1999; 31: 1120.
74. Jensen P, Moller B, Hansen S. Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens. J Am Acad Dermatol 2000; 42(2 Pt 1): 307.
75. Kishikawa H, Ichikawa Y, Yazawa K, et al. Malignant neoplasm in kidney transplantation. Int J Urol 1998; 5: 521–525.
76. Kuypers DR, Malaise J, Claes K, et al. Secondary effects of immunosuppressive drugs after simultaneous pancreas-kidney transplantation. Nephrol Dial Transplant 2005; 20 Suppl 2: ii33–ii39.
77. Loeffelbein DJ, Szilinski K, Holzle F. Immunosuppressive regimen influences incidence of skin cancer in renal and pancreatic transplant recipients. Transplantation 2009; 88: 1398–1399.
78. McGeown MG, Douglas JF, Middleton D. One thousand renal transplants at Belfast City Hospital: Post-graft neoplasia 1968-1999, comparing azathioprine only with cyclosporin-based regimes in a single centre. Clin Transpl 2000; 193–202.
79. Marcen R, Pascual J, Tato AM, et al. Influence of immunosuppression on the prevalence of cancer after kidney transplantation. Transpl Proc 2003; 35: 1714–1716.
80. Mudigonda T, Levender MM, O'Neill JL, West CE, Pearce DJ, Feldman SR. Incidence, risk factors, and preventative management of skin cancers in organ transplant recipients: A review of single- and multicenter retrospective studies from 2006 to 2010. Dermatol Surg 2013; 39(3 Pt 1): 345–364.
81. Sheil AG, Flavel S, Disney AP, Mathew TH, Hall BM. Cancer incidence in renal transplant patients treated with azathioprine or cyclosporine. Transpl Proc 1987; 19(1 Pt 3): 2214–2216.
82. Shuttleworth D, Marks R, Griffin PJ, Salaman JR. Epidermal dysplasia and cyclosporine therapy in renal transplant patients: A comparison with azathioprine. Br J Dermatol 1989; 120: 551–554.
83. Stratta P, Morellini V, Musetti C, et al. Malignancy after kidney transplantation: Results of 400 patients from a single center. Clin Transplant 2008; 22: 424–427.
84. Tessari G, Naldi L, Boschiero L, et al. Incidence and clinical predictors of a subsequent nonmelanoma skin cancer in solid organ transplant recipients with a first nonmelanoma skin cancer: A multicenter cohort study. Arch Dermatol 2010; 146: 294–299.
85. Tremblay F, Fernandes M, Habbab F, deB Edwardes MD, Loertscher R, Meterissian S. Malignancy after renal transplantation: Incidence and role of type of immunosuppression. Ann Surg Oncol 2002; 9: 785–788.
86. Ulrich C, Schmook T, Sachse MM, Sterry W, Stockfleth E. Comparative epidemiology and pathogenic factors for nonmelanoma skin cancer in organ transplant patients. Dermatol Surg 2004; 30(4 Pt 2): 622–627.
87. Watorek E, Boratynska M, Smolska D, Patrzalek D, Klinger M. Malignancy after renal transplantation in the new era of immunosuppression. Ann Transplant 2011; 16: 14–18.
88. Wisgerhof HC, van der Boog PJ, de Fijter JW, et al. Increased risk of squamous-cell carcinoma in simultaneous pancreas kidney transplant recipients compared with kidney transplant recipients. J Invest Dermatol 2009; 129: 2886–2894.
89. Zavos G, Karidis NP, Tsourouflis G, et al. Nonmelanoma skin cancer after renal transplantation: A single-center experience in 1736 transplantations. Int J Dermatol 2011; 50: 1496–1500.